CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

Websitevincicapital.ch
Phone41-21-693-92-34
Emailinfo@vincicapital.ch
Employees
Founded2003
DescriptionSwiss PE firm

Funds

Offices

HQ
PSE, Bâtiment C
Lausanne, CH-1015, CHE

Tags

VINCI CAPITAL

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.

Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operational background in growth, turn-around, consolidation, IPOs and M&A situations.

Recent Milestones

Investments

Company Date Round Size Participants
SENSIMED 11/12Series C$17.9M3
Anergis 3/11Series A$20M3
SolvAxis 2/10Venture Round$4.55M3
Evolva 12/09Series B$16M7
Evolva 12/09Series B$27.5M4
Omnisens 9/08Venture Round$5.32M1
Datamars 11/06Venture Round$8.88M5
Kuros Biosurgery 10/05Venture Round€3.6M6
immatics biotechnologies 4/05Series B$7.5M7
Kuros Biosurgery 1/05Series B€4M6

Videos

Sources

  1. Sensimed Raises CHF17M Series C for Noninvasive Glaucoma Diagnostic (pevc.dowjones.com) [edit]
  2. Startup biotech lands $20M A round for Ph2 allergy trial (fiercebiotech.com) [edit]
  3. EDGAR [edit]
  4. Evolva Goes Public In Reverse Merger, Raises $43M (fis.dowjones.com) [edit]
  5. Evolva, SA: Series B $27.5M (onbiovc.com) [edit]
  6. OMNISENS RAISES CHF 6,000,000 VENTURE FUNDING (omnisens.ch) [edit]
  7. EDGAR [edit]
  8. KUROS BIOSURGERY AG RAISES CHF 5.6M (€ 3.6M) IN ADDITIONAL FUNDING (kuros.ch) [edit]
  9. EDGAR [edit]
  10. KUROS BIOSURGERY AG EXERCISES OPTION FOR CHF 6.1M (€ 4M) INVESTMENT (kuros.ch) [edit]
Edit This Page
Last Edited 4/30/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

Recent Incoming Links

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy